Safety and Efficacy of Consolidative Stereotactic Radiotherapy for Oligo-Residual EGFR-mutant Non-Small Cell Lung Cancer after First-Line Third-Generation EGFR-tyrosine Kinase Inhibitors: a Single-Arm, Phase 2 Trial